This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Galcanezumab parenteral

Updated 2 Feb 2023 | Migraine prophylaxis


Injection of galcanezumab.

Drugs List

  • EMGALITY 120mg/1ml solution for injection pre-filled pen
  • galcanezumab 120mg/1ml solution for injection pre-filled device
  • Therapeutic Indications


    Migraine in adults: prophylaxis

    Prophylaxis of migraine in adults who have at least 4 migraine days per month.



    Initial loading dose: 240mg

    Maintenance dose: 120mg once a month

    Additional Dosage Information

    Missed doses
    If a missed dose occurs, inject as soon as possible and then continue with monthly dosing.


    Galcanezumab is for subcutaneous injection only.


    Children under 18 years

    Precautions and Warnings

    Patients over 65 years
    Severe cardiovascular disorder
    Severe hepatic impairment
    Severe renal impairment

    Advise ability to drive/operate machinery may be affected by side effects
    Treatment to be initiated by specialist
    Record name and batch number of administered product
    Self-admin. - only if adequately trained and have access to expert advice
    Assess benefit within 3 months and evaluate continued need regularly
    Discontinue if severe hypersensitivity reactions occur

    Pregnancy and Lactation


    Galcanezumab is contraindicated during pregnancy.

    The manufacturer suggests it is preferable to avoid using galcanezumab during pregnancy.

    At the time of writing there is limited published data regarding the use of galcanezumab during pregnancy. Human immunoglobulin is known to cross the placenta. Animal studies do not indicate reproductive toxicity.


    Use galcanezumab with caution during breastfeeding.

    The manufacturer advises caution if galcanezumab is used when breastfeeding.

    It is unknown whether galcanezumab is excreted in human milk. Human IgG is excreted into the milk during the first few days after birth although levels decrease soon afterwards, a risk to a breastfed infant cannot be excluded. The use of galcanezumab could be considered after this period if clinically needed. Effects on exposed infants are unknown.

    Side Effects

    Bruising at injection site
    Erythema at injection site
    Local pain (injection site)
    Local reaction at injection site
    Swelling (injection site)


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: November 2021

    Reference Sources

    Summary of Product Characteristics: Emgality 120mg solution for injection in pre-filled pen. Eli Lilly and Company Ltd. Revised September 2021.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.